Albuminuria is the hallmark of both primary and secondary proteinuric glomerulopathies,
including focal segmental glomerulosclerosis (FSGS), obesity-related nephropathy, and …

Abstract In 2020, the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney
Disease (DAPA-CKD) trial first demonstrated that inhibition of the sodium–glucose …

Ischemic stroke is a devastating disease exhibiting a dismal prognosis due to overactive
inflammation in the early stage and poor endogenous angiogenesis capacity in the late …

Fluorescence microscopy, in particular immunofluorescence microscopy, has been used
extensively for the assessment of kidney function and pathology for both research and …

Diabetic kidney disease (DKD) is one of the most important comorbidities for patients with
diabetes, and its incidence has exceeded one tenth, with an increasing trend. Studies have …

Diabetic kidney disease (DKD) is a severe DM complication. While complement C5 up‐
regulation and gut dysbiosis are found in T2DM, their roles in DKD are unclear. Here, we …

Treatments with sodium–glucose 2 cotransporter inhibitors (SGLT2i) or endothelin receptor
antagonists (ERA) have shown cardiorenal protective effects. The present study aimed to …

Background The NLRP3 inflammasome integrates several danger signals into the activation
of innate immunity and inflammation by secreting IL-1β and IL-18. Most published data …

Background The sodium–glucose cotransporter-2 (SGLT2) inhibitor empagliflozin lowers
blood glucose via reduced tubular reabsorption of filtered glucose and is an important new …

We have performed a systematic review of studies reporting on the renal effects of SGLT2
inhibitors in rodent models of diabetes. In 105 studies, SGLT2 inhibitors improved not only …